Bayer is discontinuing its Calantic Digital Solutions AI platform and ceasing Blackford Analysis services, signaling a major retreat from the radiology AI platform sector.
Key Details
- 1Bayer will exit the radiology AI software platform business, discontinuing Calantic and Blackford Analysis offerings.
- 2Calantic was launched in 2022 and built on Blackford's platform, which Bayer fully acquired in 2023.
- 3Blackford's platform currently hosts over 150 third-party AI apps from more than 60 developers across multiple clinical domains.
- 4A dedicated Bayer team will handle the transition, honoring existing contracts; future sale plans for Blackford are not confirmed.
- 5Industry experts suggest the move may trigger a consolidation wave in the radiology AI platform market and signal underlying adoption and integration challenges.
Why It Matters
Bayer’s withdrawal removes a key player and nearly 10% of spending from the global radiology AI platform ecosystem, raising concerns about the long-term viability of the platform model and potentially slowing broader AI adoption in radiology due to market uncertainty and loss of confidence.
Source
AuntMinnie
Related News
•Radiology Business
Cloud-Native AI Architectures Drive Efficiency in Radiology
Cloud-native AI systems are advancing radiology by improving workflow integration, scalability, and software management.
•Radiology Business
DeepHealth's Prostate AI Gains FDA Clearance for MRI Workflows
DeepHealth, a RadNet subsidiary, received FDA clearance for its AI solution to assist prostate cancer detection and MRI workflow.
•AuntMinnie
Human-AI Collaboration Achieves 99.2% Sensitivity for PE Detection in CTPA
A large study confirms that combining radiologists with FDA-cleared AI significantly improves pulmonary embolism detection on CTPA.